Clinical Trials Logo

Clinical Trial Summary

We have developed a prototype PET insert device that can be integrated into a clinical PET/computed tomography (CT) scanner to improve its image resolution to approximately 2.5 mm in all 3 dimensions within a reduced imaging field of view (FOV). This zoom-in imaging capability provides 6-fold improvement in volumetric image resolution over the current state-of-the-art clinical PET scanner, offering a tremendous opportunity for cancer imaging applications, in particular for those cases where a lymph node involvement will drastically alter the patient management plan. Accurate diagnosis and staging of head-and-neck cancer is known to be challenging because of the complex anatomy and large number of lymph nodes involved in this region. As a result, head and neck cancer imaging is an ideal candidate for evaluating the clinical usefulness of this novel imaging device.


Clinical Trial Description

In this project, we propose to conduct an exploratory clinical trial to investigate the effectiveness of this novel imaging device in detecting small lesions and lymph node involvements in the head and neck region, and compare its results to those obtained from a clinical PET/CT scanner. More specifically, we propose to (1) recruit 5 patients who have confirmed head and neck cancer and are scheduled to receive a whole-body PET/CT scan followed by surgical operation to remove the primary tumor and the regional lymph nodes. These patients will be imaged by a state-of-the-art PET/CT scanner using the standard whole-body PET/CT imaging protocol as standard of care for initial staging. On another day, following consent to participate in this research protocol, A patient will undergo images of the head and neck region using the same type scanner with and without our novel PET insert device attached; (2) The images obtained from the PET insert device will be reviewed by experienced nuclear medicine physicians to identify the extent of lymph node involvement. The PET insert images will be compared to the standard clinical PET/CT images. A detailed image obtained for purposes of research, centered at the level of the head and neck, acquired for approximately 3 times the length of time the standard clinical image is obtained for will also be compared to the PET insert image. Images will also be compared to the pathology report of the surgically removed specimen. (3) Estimate the performance of lesion detection for different sizes of tumors using the standard PET/CT scanner as well as the PET insert device. ;


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01133262
Study type Observational
Source Washington University School of Medicine
Contact
Status Withdrawn
Phase N/A
Start date June 2010
Completion date December 2011

See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT06236464 - Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Terminated NCT04659369 - Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT02572778 - Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Terminated NCT01488318 - Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT00999700 - Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Phase 3
Completed NCT02565758 - ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02543476 - SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Recruiting NCT03938012 - Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Terminated NCT02124850 - A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab Phase 1
Active, not recruiting NCT03313804 - Priming Immunotherapy in Advanced Disease With Radiation Phase 2
Recruiting NCT05208762 - A Study of SGN-PDL1V in Advanced Solid Tumors Phase 1
Terminated NCT04453046 - Hemopurifier Plus Pembrolizumab in Head and Neck Cancer N/A
Completed NCT01758731 - Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History Phase 1
Completed NCT02473731 - A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Phase 1
Completed NCT02022098 - Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial N/A
Completed NCT01458392 - Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2
Completed NCT02882308 - Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. Phase 2